NF2 and lung cancer: TAZ-CAMTA1 fusion in epithelioid hemangioendothelioma (EHE) [207, 208], and NF2 deletion in MPM [57] can also predict response to TEAD inhibitors; however, these genetic alterations are extremely rare in lung cancer [57].